PPARG and breast cancer: It has been reported that sub-saturated doses of the TZDs, troglitazone and rosiglitazone, activate the autophagic flux in a PPARγ-dependent manner through the upregulation of the hypoxia-inducible factor 1 (HIF1)α in MDA-MB-231 breast cancer cells [21].